Tillater meg å stjele denne fra @Ramsess og poste hær, lukter fimaVACC laaaang veiii 
The rationale for neoantigen vaccines involves the clear shortcomings of checkpoint inhibitors like nivolumab, pembrolizumab (Merck’s Keytruda), and ipilimumab (Bristol’s Yervoy). Each blocks the molecular force field that tumor cells create to fend off immune cells that try to attack them. With the force field removed, T cells and others supposedly have a clear shot at the tumors.
“But checkpoint drugs rely on the T cells that are there,” said Dr. Patrick Ott of Dana-Farber Cancer Institute in Boston, a lead researcher in the Neon trial. In some patients, the natural T cell army is sufficient to eliminate tumors, as Keytruda did when former President Jimmy Carter received it in 2015 for melanoma that had spread to his brain. But in other patients, who for whatever reason do not produce enough T cells or whose T cells eventually lose their oomph (a phenomenon called exhaustion), the checkpoint drugs either do not work in the first place or eventually stop working.
So while the checkpoint drugs rely on an all-volunteer T-cell army, neoantigen vaccines act like a draft board calling up as many recruits as possible.
satser på at denne høsten blir det mye sol 
